# EDGAR Filing Document

**Accession Number:** 0001843762
**File Stem:** 0001104659-23-027657
**Filing Date:** 2023-3
**Character Count:** 1928
**Document Hash:** c966fd0e1ea05eda66fd0932e15d7ea9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-027657.hdr.sgml**: 20230331

**ACCESSION NUMBER**: 0001104659-23-027657

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230302

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** EQRx, Inc.
- **CENTRAL INDEX KEY:** 0001843762
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 861691173
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 50 HAMPSHIRE STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139
- **BUSINESS PHONE:** (617) 315-2255

**MAIL ADDRESS:**
- **STREET 1:** 50 HAMPSHIRE STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CM Life Sciences III Inc.
- **DATE OF NAME CHANGE:** 20210201

**EQRX, INC.**

50 Hampshire Street

Cambridge MA 02139

**<u>VIA EDGAR</u>**

March 2, 2023

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

**Re: EQRx, Inc.** 

**Acceleration Request for Registration Statement on Form S-3** 

**Filed February 23, 2023** 

**File No. 333-269972**

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, EQRx, Inc. hereby requests that the effective date and time of the above-referenced registration statement be accelerated to March 3, 2023, at 4:30 p.m., Eastern Time, or as soon thereafter as practicable.

If you have any questions regarding this request, please contact William Collins of Goodwin Procter LLP at (617) 570-1447.

---

| |
|:---|
| Sincerely, |
| **EQRX, INC.** |
| /s/ Jami Rubin |
| Jami Rubin |
| Chief Financial Officer |

---

cc: Melanie Nallicheri, *EQRx, Inc.* <br> Dina Ciarimboli, *EQRx, Inc.* 

William Collins, *Goodwin Procter LLP*

Marianne Sarrazin, *Goodwin Procter LLP*